Friday, January 21, 2022

ContraFect Corporation (CFRX) Stock Could See Substantial Growth with Impressive Capital Generation

ContraFect Corporation (CFRX) hit USD$4.11 at market close on April 14th, 2021, having seen an upswing of 4.05%. Investors hope this is a continuation of growth in stock prices that will continue its upward trend.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


BARDA Contract

CFRX stock prices saw a sharp spike following the announcement of a USD$86.8 million contract with the Biomedical Advanced Research and Development Authority (BARDA). This contract intends to provide ongoing support for the third phase of the ongoing DISRUPT trial. The first installment will see CFRX receive USD$9.8 million, with the rest being provided on an ongoing basis depending on clinical progress and success.

High Hopes for Success


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


Should the trial be completed successfully, the capital provided by BARDA will be used towards supporting additional developmental work necessitated by the FDA for its approval. The funds are also eligible to cover post-approval costs, including but not limited to pediatric study completion.

CARB-X Award

CFRX announced an award from CARB-X, totaling up to USD$18.9 million, in mid-2020. The initial tranche amounts to USD$4.9 million, with the rest being released dependent on the achievement of project milestones for IND-enabling activities for CF-370. IND-enabling activities are anticipated to go into the first phase of the trial in the first half of 2022, with studies currently being conducted to facilitate that goal.

What this Mean for Investors

These contracts serve to instill investor confidence in the highly competitive work CFRX is conducting, with a probabilistic, evidence-based outlook of a positive outcome by the parties awarding the contracts. The acquisition of capital through non-dilutive financing has also been highly appealing for investors both current and prospective.

Why did Stock Price Plummet?

CFRX stock prices, however, plummeted following the news of a public offering of 11.5 million shares of its stock, priced at USD$5 per share, to net the company USD$53.7 million. Despite the dilution that investors thought they had avoided, stock prices are on the cusp of further growth in light of their strong financial position in Q1 of 2020.

Latest news

Here’s the Reason of Sonoma Pharmaceuticals, Inc. (SNOA) Stock Gaining Momentum in Aftermarket.

Sonoma Pharmaceuticals, Inc. (SNOA) is an innovative and leading global brand engaged in the development of stabilized hypochlorous acid products for different applications including...

Looking Under The Hood: What’s Happening To Bee Vectoring Technologies (BEVVF) Stock

Bee Vectoring Technologies International Inc (BEVVF) closed up 24.71 percent on Wednesday at $0.3280, and has been trading in a day range of $0.2721...

Best cannabis stock investment could lead to great profits in the near future

In recent months, there has been much debate about which are the best cannabis stocks. There are several states where recreational marijuana is legal,...

Stealth BioTherapeutics Inc. (MITO) stock rose during after-hours, provided no current update.

Stealth BioTherapeutics Inc. (NASDAQ: MITO) stock plunged by 3.57% at last close whereas the MITO stock price gains by 6.17% in the after-hour trading...

Related news

Here’s the Reason of Sonoma Pharmaceuticals, Inc. (SNOA) Stock Gaining Momentum in Aftermarket.

Sonoma Pharmaceuticals, Inc. (SNOA) is an innovative and leading global brand engaged in the development of stabilized hypochlorous acid products for different applications including...

Looking Under The Hood: What’s Happening To Bee Vectoring Technologies (BEVVF) Stock

Bee Vectoring Technologies International Inc (BEVVF) closed up 24.71 percent on Wednesday at $0.3280, and has been trading in a day range of $0.2721...

Best cannabis stock investment could lead to great profits in the near future

In recent months, there has been much debate about which are the best cannabis stocks. There are several states where recreational marijuana is legal,...

Stealth BioTherapeutics Inc. (MITO) stock rose during after-hours, provided no current update.

Stealth BioTherapeutics Inc. (NASDAQ: MITO) stock plunged by 3.57% at last close whereas the MITO stock price gains by 6.17% in the after-hour trading...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1745

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam